Myopia
Conditions
Keywords
Atropine, Myopia, Axial elongation
Brief summary
This randomized controlled trial aims to evaluate the efficacy and safety of low-dose topical atropine sulphate (0.05%), a non-selective muscarinic antagonist, in slowing the progression of myopia and ocular axial elongation in children. The study will be conducted at Mansoura Ophthalmic Center, Mansoura University, Egypt, from October 2025 to october 2027. Eligible participants are myopic children attending the outpatient clinic during the study period. Participants will be stratified into three groups according to baseline myopia severity (low, moderate, and high). Each child will be randomized to receive one drop of atropine 0.05% in one eye and one drop of placebo in the fellow eye nightly for 24 months. The allocation of treatment to right or left eye will be randomized to avoid laterality bias. Study Outcomes * Primary Outcome o Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation. * Secondary Outcomes * Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%. * Best-corrected distance visual acuity (BCVA). * Sample Size The primary endpoint of this trial is the change in ocular axial length (AL) over 24 months, analyzed as a paired comparison between the atropine-treated and placebo-treated eyes within each child. Sample size estimation was based on previously published data reporting mean axial elongation of 0.115 ± 0.11 mm in atropine-treated eyes compared with 0.303 ± 0.12 mm in placebo-treated eyes, yielding a mean difference of 0.188 mm. Assuming an inter-eye correlation of 0.6, the standard deviation of the paired difference is estimated at approximately 0.10 mm, giving an effect size of d = 1.88. Using a two-tailed paired t-test with α = 0.05 and 90% power, the minimum required sample size is 12 children.
Interventions
DRUGAtropine 0.05% Eye drops
The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
DRUGPlacebo ophthalmic solution
The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
Sponsors
Mansoura University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Study medications (atropine 0.05% and placebo) will be supplied in identical bottles with identical labeling and packaging to maintain blinding. The allocation of treatment to the right or left eye will be randomized and concealed. Participants, their parents/guardians, the treating investigators, and outcome assessors will remain blinded to the allocation throughout the study. Only the study pharmacist (not involved in outcome assessment) will have access to the randomization code until study completion or unless unmasking is required for safety reasons.
Intervention model description
Each participant will receive one drop of atropine 0.05% in one randomly assigned eye and one drop of placebo in the fellow eye nightly for 24 months. No other myopia control treatments will be permitted during the study period.
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Myopia of at least -1.0 D in both eyes, astigmatism of less than 2.0 D, anisometropia of objective spherical equivalent ≤ 1.50 D. * Documented myopic progression of at least 0.5 D in the past one year.
Exclusion criteria
* Children with ocular or systemic diseases that potentially influence myopia or refractive power. * Ocular diseases, e.g., cataracts, glaucoma * Posterior segment hereditary and acquired pathological disorders. * History of any previous ocular surgery. * History of any ocular injuries. * Previous use of interventions (such as atropine, pirenzepine, orthokeratology lens, or other optical methods) for myopia control * Allergy to atropine, cyclopentolate or benzalkonium chloride
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ocular axial length (AL) | 2 years | Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in spherical equivalent refraction (SER | 24 months | Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%. |
| Best-corrected distance visual acuity (BCVA). | 24 months | — |
Contacts
Primary ContactGhada H. Allam, Dr
Outcome results
None listed